Trials / Unknown
UnknownNCT04735679
Characterization of Pulmonary Microbiome in Cystic Fibrosis Patients
Multi-omic Longitudinal Characterization of Pulmonary Microbiome in Cystic Fibrosis Patients
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 250 (estimated)
- Sponsor
- University Hospital, Montpellier · Academic / Other
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The composition and role of the pulmonary microbiota is not yet well described in cystic fibrosis patients. The objective of our longitudinal follow-up of primary colonised patients is to show the presence of a link between the composition of the microbiota and the effectiveness of antibiotic therapy. All patients followed at the Montpellier CF center will be asked to participate in this cohort. All patients have a regular follow-up every 1 to 6 months and will be asked at each visit to keep their sputum sample in excess of the analyses requested for their follow-up
Detailed description
The composition and role of the pulmonary microbiota is not yet well described in cystic fibrosis patients. According to our hypothesis, the lung microbiota shapes the lung environment of cystic fibrosis patients and modifies the effectiveness of antibiotic treatments and the course of the disease. The objective of our longitudinal follow-up of primary colonised patients is to show the presence of a link between the composition of the microbiota and the effectiveness of antibiotic therapy. Finally, the management of first colonisations could justify the characterisation of the microbiota in order to develop innovative diagnostic tests for the follow-up of patients suffering from cystic fibrosis and possibly the identification of new therapeutic agents based on the microbiota. All patients followed at the Montpellier CF centre will be asked to participate in this cohort. All patients have a regular follow-up every 1 to 6 months and will be asked at each visit to keep their sputum sample in excess of the analyses requested for their follow-up.
Conditions
Timeline
- Start date
- 2021-01-01
- Primary completion
- 2023-12-01
- Completion
- 2023-12-31
- First posted
- 2021-02-03
- Last updated
- 2021-02-05
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04735679. Inclusion in this directory is not an endorsement.